Cagrilintide Dosage: What the Research Shows

Cagrilintide is a long-acting amylin analog that has drawn a lot of interest in the weight-management space, especially paired with semaglutide in the investigational combination known as CagriSema. Because it's so often discussed alongside GLP-1 medicines, people naturally search for a "cagrilintide dosage" — but it's worth being clear up front about what that number actually represents.

First, an important caveat

Cagrilintide is not an FDA-approved finished drug. It has been studied in clinical trials, but it is not sold as an approved medication for weight loss or any other condition. Any information here reflects how it has been used in research settings, not a prescription or a recommendation. Amylin analogs affect appetite, gastric emptying, and blood sugar signaling, so decisions about them belong with a licensed clinician who can weigh your personal health picture. This page is educational only.

How amylin analogs like cagrilintide work

Amylin is a hormone co-secreted with insulin from the pancreas. It helps slow how quickly the stomach empties, promotes a feeling of fullness, and dampens the after-meal rise in glucagon. Native amylin is unstable and clumps together, which is why researchers engineered analogs like cagrilintide to be more stable and long-acting — designed for roughly once-weekly subcutaneous injection. In trials, that mechanism complements GLP-1 receptor agonists, which is why the pairing with semaglutide has been so heavily studied.

Dosage ranges seen in clinical studies

In published research, cagrilintide has been evaluated across a spread of weekly doses, commonly cited in the range of roughly 0.3 mg up to 2.4 mg once weekly, with the higher end (around 2.4 mg) being the dose most associated with meaningful weight change in monotherapy studies. In the CagriSema combination, cagrilintide has been paired with 2.4 mg of semaglutide. These are trial figures — not a personal protocol — and they were reached under close medical supervision with structured monitoring.

The single most important theme across every study is gradual titration. Researchers did not start participants at the top dose. They began low and stepped up over a period of weeks to let the body adapt, which is the same logic used with approved GLP-1 medicines like tirzepatide and semaglutide. Starting low and going slow is how the nausea, fullness, and GI effects are kept manageable.

Why titration matters so much

Amylin analogs slow gastric emptying, so the most common early side effects are nausea, reduced appetite, and occasional GI upset. A slow escalation schedule gives your system time to adjust and tends to reduce how intense those effects feel. This is exactly the same reasoning behind the step-up schedules you'll see in our dosing schedule guide for other investigational compounds. The specifics differ, but the principle — patience over speed — carries across the whole category.

Reconstitution and measurement basics

Many research-grade peptides arrive as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before it can be measured. This is where a lot of confusion — and a lot of dosing errors — happen. The amount of water you add determines the concentration, and the concentration determines how many "units" on a syringe correspond to a given milligram dose.

If you're trying to understand how a powder translates into an actual injection volume, our reconstitution calculator walks through the math so you can see how milligrams, milliliters, and syringe units relate. Getting this right is not optional busywork — a miscalculation can turn a small intended dose into a large one. Working these numbers out with a clinician, rather than guessing, is the safe path.

Cagrilintide vs. GLP-1 medicines

People often lump cagrilintide in with GLP-1 drugs, but it belongs to a different hormone family. GLP-1 receptor agonists (like semaglutide) and dual/triple agonists (like tirzepatide and retatrutide) act on incretin pathways. Cagrilintide acts on amylin pathways. The reason they're studied together is that their mechanisms are complementary — hitting appetite and satiety from different angles. That's the whole rationale behind combination approaches, and it's why cagrilintide dosing is frequently discussed in the context of a partner drug rather than in isolation.

Tracking and consistency

Whatever a clinician decides, consistency helps — same day each week, careful records of dose and any side effects, and honest notes about how you feel. A simple dose tracker makes it easier to spot patterns, remember your last injection, and share accurate information at follow-up visits. Good records also make it much harder to accidentally double-dose or lose track of where you are in a titration.

Safety notes worth repeating

• Not a substitute for medical care. Cagrilintide is investigational; a licensed clinician should be involved in any decision.
• Slow titration reduces side effects. The trials that reported the best tolerability all used gradual escalation.
• Measurement errors are the real risk. Reconstitution math matters — double-check every calculation.
• Watch how you feel. Persistent vomiting, severe abdominal pain, or signs of dehydration warrant prompt medical attention.

Bottom line: the "cagrilintide dosage" numbers you'll see online come from clinical research, not from a one-size-fits-all prescription. Treat them as context for a conversation with a qualified professional, not as instructions. Understanding the mechanism, respecting the titration principle, and getting the reconstitution math right are the fundamentals worth internalizing before anything else.